Luminex Corp represents a strong commitment to innovation, quality, and excellence. The company's corporate philosophy revolves around creating cutting-edge solutions for life science research and clinical diagnostics. Luminex Corp aims to improve patient outcomes by providing advanced multiplexing technology and instrumentation. Their values include integrity, collaboration, and customer satisfaction. Luminex Corp consistently strives to deliver highly reliable, scalable, and cost-effective products that meet the evolving needs of the scientific community. With a focus on advancing healthcare, Luminex Corp consistently fosters partnerships and promotes a culture of continuous improvement.

Luminex Corp is primarily present in the United States, with its headquarters located in Austin, Texas. As a global leader in molecular diagnostics and life sciences, Luminex also has a significant presence in various other countries. The company operates in Europe, including the United Kingdom, Germany, France, Italy, Spain, and the Netherlands. Luminex also has a strong presence in Asia, particularly in Japan, China, and India. Additionally, Luminex Corp has strategic partnerships and distribution networks in many other regions around the world, ensuring its products and solutions reach customers worldwide.

Luminex Corp has achieved several significant milestones throughout its history. Some notable achievements include the development and introduction of its revolutionary xMAP Technology, which revolutionized the field of multiplexing and allowed for the simultaneous analysis of multiple analytes in a single sample. Additionally, Luminex Corp received FDA clearance for its breakthrough instrument, the ARIES System, enabling automated molecular diagnostic testing. The company's commitment to innovation and dedication to improving healthcare further led to the successful launch of the VERIGENE System, which offers rapid and accurate identification of infectious diseases. These milestones demonstrate Luminex Corp's continuous efforts in advancing scientific research and providing transformative solutions to the biomedical industry.

Luminex Corp is a leading biotechnology company known for its groundbreaking solutions in the life sciences and diagnostics industries. Founded in 1995, Luminex Corp has a rich history of innovation and has continuously evolved to meet the ever-changing needs of the healthcare sector. With a focus on developing and commercializing multiplexed solutions, Luminex Corp has revolutionized the way diseases are diagnosed and monitored. The company's proprietary xMAP® technology platform allows for simultaneous analysis of multiple analytes in a single sample, enhancing efficiency and accuracy. Throughout its history, Luminex Corp has been committed to improving patient outcomes and driving advancements in molecular diagnostics and personalized medicine. Their dedication to research and development has positioned them as a trusted partner in the global healthcare community.

The main competitors of Luminex Corp in the market include Bio-Rad Laboratories, BioMérieux, Thermo Fisher Scientific, and Fluidigm Corporation.

Luminex Corp is primarily active in the healthcare and life sciences industries.

The business model of Luminex Corp involves developing, manufacturing, and marketing proprietary biological testing technologies. This includes systems and assays for clinical diagnostics and life science research. Luminex specializes in multiplexing, which enables the simultaneous measurement of multiple analytes in a single sample. By providing innovative solutions, Luminex aims to enhance healthcare and address significant challenges in areas such as infectious diseases, cancer, and genetic testing. The company's commitment to advancing healthcare through its versatile platform has positioned Luminex Corp as a leading player in personalized medicine and diagnostics.

De Luminex K/W is 11,94.

De Luminex KUV is 2,59.

De AlleAktien Kwaliteitsscore voor Luminex is 5/10.

De verwachte Luminex omzet is 653,50 mln. USD.

De verwachte Luminex winst is 141,94 mln. USD.

The Luminex Corporation is a leading provider of diagnostic and clinical molecular products that enable fast, reliable, and accurate disease diagnosis. The company is headquartered in Texas and operates worldwide. The business model of the Luminex Corporation consists of various divisions tailored to meet the different needs of customers. These include molecular diagnostics, life sciences, and life science research. Under the molecular diagnostics division, the Luminex Corporation offers a wide range of products used for disease and infection diagnosis. Examples include the ARIES® system for diagnosing respiratory infections and the NxTAG® system for rapid and reliable infection diagnosis. The life sciences division provides products and services for disease research and drug development. Examples include the MagPIX system for fast and precise multiplex testing and the FlexMAP 3D system for high-throughput biomarker discovery. In the life science research division, Luminex offers various products and services for scientific research. Examples include the xMAP® system for biomarker measurement and the Guava® system for automated cell analysis. In addition to these divisions, Luminex Corporation also offers extensive service and support. The company works closely with its customers to develop customized solutions and meet their needs. Luminex Corporation's business model is based on innovative technologies and collaboration with customers and partners. The company continuously invests in research and development to offer competitive products and gain a competitive advantage. In summary, the Luminex Corporation provides a wide range of diagnostic and clinical molecular products that enable doctors and scientists to make accurate and fast disease diagnoses. With a comprehensive range of products and services, as well as extensive support, Luminex Corporation ensures customer needs are met and maintains a strong position in the market.

Luminex keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Luminex of het bedrijf keert geen dividend uit.

De ISIN van Luminex is US55027E1029.

Het WKN van Luminex is 936597.

De ticker van Luminex is LMNX.

Binnen de laatste 12 maanden betaalde Luminex een dividend van 0,37 USD . Dit komt overeen met een dividendrendement van ongeveer 1,00 %. Voor de komende 12 maanden zal Luminex naar verwachting een dividend van 1,72 USD betalen.

De dividendrendement van Luminex is momenteel 1,00 %.

Luminex betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden oktober, januari, april, juli.

Luminex betaalde de afgelopen 8 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 1,72 USD verwacht. Dit komt overeen met een dividendrendement van 4,66 %.

Luminex wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Luminex van 8-7-2021 ter hoogte van 0,1 USD te ontvangen, moest je het aandeel voor de ex-datum op 16-6-2021 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 8-7-2021.

In het jaar 2023 heeft Luminex 0,79 USD aan dividenden uitgekeerd.

De dividenden van Luminex worden in USD uitgekeerd.